All In MedTech

FDA Clearance Tracker · P170035

Bausch + Lomb Ultra (samfilcon A) Contact Lenses

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Apr 30, 2018 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Apr 30, 2018

Approved

Time to decision

180 days

Received Nov 1, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P170035
Device name
Bausch + Lomb Ultra (samfilcon A) Contact Lenses
Applicant location
Rochester, NY
Received
Nov 1, 2017
Decided
Apr 30, 2018
Decision
Approved
Supplements
18 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

Approval for the Bausch + Lomb Ultra (samfilcon A) Contact Lenses. These devices are indicated for:Single Vision Spherical (SVS) Vision CorrectionThe BAUSCH + LOMB ULTRA (samfilcon A) Contact Lens is indicated for extended wear for up to 7 days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care practitioner. The lens is indicated for the correction of refractive ametropia (myopia and hyperopia) in aphakic and/or not-aphakic persons with non-diseased eyes, exhibiting astigmatism of 2.00 diopters or less, that does not interfere with visual acuity.Presbyopia Vision CorrectionThe BAUSCH + LOMB ULTRA (samfilcon A) Contact Lens for Presbyopia is indicated for extended wear for up to 7 days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care practitioner. The lens is indicated for the correction of refractive ametropia (myopia, hyperopia and astigmatism) and presbyopia in aphakic and/or not-aphakic persons with non-diseased eyes, exhibiting astigmatism of 2.00 diopters or less, that does not interfere with visual acuity. The lens may be prescribed for add powers ranging from +0.75D to +5.00D. Astigmatism Vision CorrectionThe BAUSCH + LOMB ULTRA (samfilcon A) Contact Lens for Astigmatism is indicated for extended wear for up to 7 days between removals for cleaning and disinfection or disposal of the lens, as recommended by the eye care practitioner. The lens is indicated for the correction of refractive ametropia (myopia, hyperopia and astigmatism) in aphakic and/or not-aphakic persons with non-diseased eyes, exhibiting astigmatism up to 5.00 diopters.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LPM. The earliest in FDA's data is N16895, decided Mar 18, 1971.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Bausch and Lomb, Inc.,

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.